References
- Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science281(5381), 1305–1308 (1998).
- Cha SS, Kim MS, Choi YH et al. 2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. Immunity11(2), 253–261 (1999).
- Ashkenazi A, Pai RC, Fong S et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest.104(2), 155–162 (1999).
- Walczak H, Miller RE, Ariail K et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med.5(2), 157–163 (1999).
- Jo M, Kim TH, Seol DW et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med.6(5), 564–567 (2000).
- Nagata S. Steering anti-cancer drugs away from the TRAIL. Nat. Med.6(5), 502–503 (2000).
- Lawrence D, Shahrokh Z, Marsters S et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med.7(4), 383–385 (2001).
- Hao C, Song JH, Hsi B et al. TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res.64(23), 8502–8506 (2004).
- Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, Van Den Brink MR, Yagita H. Nature’s TRAIL – on a path to cancer immunotherapy. Immunity18(1), 1–6 (2003).
- Herbst RS, Eckhardt SG, Kurzrock R et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J. Clin. Oncol.28(17), 2839–2846 (2010).
- Soria JC, Smit E, Khayat D et al. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J. Clin. Oncol.28(9), 1527–1533 (2010).
- Soria JC, Mark Z, Zatloukal P et al. Randomized Phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J. Clin. Oncol.29(33), 4442–4451 (2011).
- Ichikawa K, Liu W, Zhao L et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat. Med.7(8), 954–960 (2001).
- Tolcher AW, Mita M, Meropol NJ et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J. Clin. Oncol.25(11), 1390–1395 (2007).
- Plummer R, Attard G, Pacey S et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin. Cancer Res.13(20), 6187–6194 (2007).
- Camidge DR, Herbst RS, Gordon MS et al. A Phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin. Cancer Res.16(4), 1256–1263 (2010).
- Trarbach T, Moehler M, Heinemann V et al. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br. J. Cancer102(3), 506–512 (2010).
- Bellail AC, Qi L, Mulligan P, Chhabra V, Hao C. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev. Recent Clin. Trials4(1), 34–41 (2009).
- Wuchter C, Krappmann D, Cai Z et al.In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kappa B activity. Leukemia15(6), 921–928 (2001).
- Bellail AC, Olson JJ, Yang X, Chen ZJ, Hao C. A20 ubiquitin ligase-mediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma. Cancer Discov.2(2), 140–155 (2012).